High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: A comparative study

Diagnostic Microbiology and Infectious Disease

Volumn 80, Issue 1, 2014, Pages 66-71

  Lora Tamayo, Jaime ^a   Parra Ruiz, Jorge ^b   Rodríguez Pardo, Dolors ^c   Barberán, José ^d   Ribera, Alba ^a   Tornero, Eduardo ^e   Pigrau, Carles ^c   Mensa, José ^e   Ariza, Javier ^a   Soriano, Alex ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d H de la Defensa   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Biofilm; Combined therapy; DAIR; Fluoroquinolone resistance; Orthopedic device infection

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; CONTROLLED STUDY; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUOROQUINOLONE RESISTANT STAPHYLOCOCCI PROSTHETIC JOINT INFECTION; FOLLOW UP; HUMAN; IMPLANT; KIDNEY INJURY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTHESIS INFECTION; RELAPSE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SINGLE DRUG DOSE; STAPHYLOCOCCAL PROSTHETIC JOINT INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; VERY ELDERLY; VOMITING; WOUND DEHISCENCE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TREATMENT OUTCOME;

EID: 84926180165     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.05.022     Document Type: Article

References (40)

1. Aboltins C.A., Page M.A., Buising K.L., Jenney A.W., Daffy J.R., Choong P.F., et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007, 13:586-591.
2. Ariza J., Euba G., Murillo O. Orthopedic device-related infections. Enferm Infecc Microbiol Clin 2008, 26:380-390.
3. Baltch A.L., Ritz W.J., Bopp L.H., Michelsen P., Smith R.P. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages in broth. Antimicrob Agents Chemother 2008, 52:1829-1833.
4. Barberán J., Aguilar L., Carroquino G., Giménez M.J., Sánchez B., Martínez D., et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006, 119:993.e7-993.e10.
5. Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006, 50:3245-3249.
6. Bradbury T., Fehring T.K., Taunton M., Hanssen A., Azzam K., Parvizi J., et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty 2009, 24:101-104.
7. Brandt C.M., Sistrunk W.W., Duffy M.C., Hanssen A.D., Steckelberg J.M., Ilstrup D.M., et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997, 24:914-919.
8. Byren I., Bejon P., Atkins B.L., Angus B., Masters S., McLardy-Smith P., et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009, 63:1264-1271.
9. Byren I., Rege S., Campanaro E., Yankelev S., Anastasiou D., Kuropatkin G., et al. Randomized controlled trial of safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 2012, 56:5626-5632.
10. Cobo J., Miguel L.G., Euba G., Rodríguez D., García-Lechuz J.M., Riera M., et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect 2011, 17:1632-1637.
11. Corona Pérez Cardona P.S., Barro Ojeda V., Rodríguez Pardo D., PigrauSerrallach C., Guerra Farfán E., Amat Mateu C., et al. Clinical experience with daptomycin for the treatment of patients with knee and hip perisprosthetic joint infections. J Antimicrob Chemother 2012, 67:1749-1754.
12. Enoch D.A., Bygott J.M., Daly M.L., Karas J.A. Daptomycin. J Infect 2007, 55:205-213.
13. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
14. Garrigos C., Murillo O., Euba G., Verdaguer R., Tubau F., Cabellos C., et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010, 54:5251-5256.
15. Gould I.M., Miró J.M., Rybak M.J. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013, 42:202-210.
16. Jogun K., Vaudaux P., Garbino J., Pagani L., Hoffmeyer P., Lew D., et al. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop 2013, 37:1375-1380.
17. Landersdorfer C.B., Bulitta J.B., Kinzig M., Holzgrabe U., Sörgel F. Penetration of antibacterials into bone. Pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009, 48:89-124.
18. Lemaire S., Van Bambeke F., Mingeot-Leclercq M.P., Tulkens P.M. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and Madin-Darby canine kidney cells. Antimicrob Agents Chemother 2007, 51:2748-2757.
19. Lora-Tamayo J., Murillo O., Iribarren J.A., Soriano A., Sánchez-Somolinos M., Baraia-Etxaburu J.M., et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013, 56:182-194.
20. Lora-Tamayo J., Euba G., Ribera A., Murillo O., Pedrero S., García-Somoza D., et al. Infected hip-hemiarthroplasties and total hip arthroplasties: differential findings and prognosis. J Infect 2013, 67:536-544.
21. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006, 44:595-597.
22. Mélard A., Garcia L.G., Das D., Rozenberg R., Tulkens P.M., Van Bambeke F., et al. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. J Antimicrob Chemother 2013, 68:648-658.
23. Moise P.A., North D., Steenbergen J.N., Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus facts and assumptions. Lancet Infect Dis 2009, 9:614-624.
24. Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.
25. Murillo O., Garrigós C., Pachón M.E., Euba G., Verdaguer R., Cabellos C., et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:4252-4257.
26. Murray P.R., Baron E.J., Jorgesen J.H., Landry M.L., Pfaller M.A. Manual of clinical microbiology 2007, ASM Press, Washington, DC. 9th ed.
27. Osmon D.R., Berbari E.F., Berendt A.R., Lew D., Zimmerli W., Steckelberg J.M., et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:e1-e25.
28. Peel T.N., Cheng A.C., Buising K.L., Choong P.F. Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective?. Antimicrob Agents Chemother 2012, 56:2386-2391.
29. Rao N., Regalla D.M. Uncertain efficacy of daptomycin for prosthetic joint infections. Clin Orthop Relat Res 2006, 451:34-37.
30. Rodríguez D., Pigrau C., Euba G., Cobo J., García-Lechuz J., Palomino J., et al. Acute hematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. Clin Microbiol Infect 2010, 16:1789-1795.
31. Safdar N., Andes D., Craig W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004, 48:63-68.
32. Saleh-Mghir A., Muller-Serieys C., Dinh A., Massias L., Crémieux A.C. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011, 55:4589-4593.
33. Senneville E., Joulie D., Legout L., Valette M., Dezèque H., Beltrand E., et al. Outcome and predictors of treatment failure in total hip and knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011, 53:334-340.
34. Sharma M., Riederer K., Chase P., Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008, 27:433-437.
35. Stewart P.S., Davison W.M., Steenbergen J.N. Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009, 53:3505-3507.
36. Tornero E., García-Oltra E., García-Ramiro S., Martínez-Pastor J.C., Bosch J., Climent C., et al. Prosthetic joint infections due to Staphylococcus aureus and coagulase-negative staphylococci. Int J Artif Organs 2012, 35:884-892.
37. Traunmüller F., Schintler M.V., Metzler J., Spendel S., Mauric O., Popovic M., et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010, 65:1252-1257.
38. Vilchez F., Martínez-Pastor J.C., García-Ramiro S., Bori G., Maculé F., Sierra J., et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infection due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect 2011, 17:439-444.
39. Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 1998, 279:1537-1541.
40. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic joint infections. N Engl J Med 2004, 351:1645-1654.